Possis' new AngioJet catheter tackles chronic clots
This article was originally published in Clinica
Executive Summary
Possis Medical has gained US go-ahead to sell a new version of its AngioJet catheter that can remove chronic clots more efficiently in larger vessels. The 6Fr DVX peripheral catheter can be used to break apart and remove thrombus from leg arteries greater than or equal to 3mm in diameter. It features a redesigned tip that creates an enhanced and enlarged circulation pattern, resulting in significantly higher thrombus removal rates, explained Possis. The Minneapolis, Minnesota firm said that as the company moved forward to explore the potential treatment of acute deep vein thrombosis in fiscal 2006, it is likely that the DVX catheter would be the "preferred investigational device for any clinical studies".
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.